(From left) Katheryne Richardson, Ted Slafsky, Sue Barnhart, Robert Popovian, Alexandra Williams, William Sarraille and Mark Ogunsusi debated 340B program data and oversight during an Oct. 9 AVBCC panel in New York City.
The American Hospital Association, the Maine Hospital Association and four hospitals filed an Oct. 9 lawsuit to block HRSA's revised 340B rebate pilot in a Maine federal district court.
Novo's blockbuster GLP-1 drug Ozempic/Wegovy/Rybelus is one of two eligible drugs that was not included in HRSA's recent 340B rebate model plan approvals.
The Ohio Department of Health recently released detailed, individual 340B covered entity reports based on a provider reporting law enacted last summer.
